TNFRSF9 and breast neoplasm: In vitro treatment of human breast tumor-derived multicellular cultures with anti-HER2 antibodies induced the activation of CD16+ NK cells in a dose-dependent manner, as evidenced by the up-regulation of CD137 (Fig. 4B, C).